Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
复制标题
DOI：
10.1371/journal.pone.0092784
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Cheng JS
中科院分区：
文献类型：
--
作者：
Tsai WL;Lai KH;Liang HL;Hsu PI;Chan HH;Chen WC;Yu HC;Tsay FW;Wang HM;Tsai HC;Cheng JS
The optimal treatment for huge unresectable hepatocellular carcinoma (HCC) remains controversial. The outcome of transcatheter arterial chemoembolization (TACE) for patients huge unresectable HCC is generally poor and the survival benefit of TACE in these patients is unclear. The aim of the study is to compare the effect of hepatic arterial infusion chemotherapy (HAIC) versus symptomatic treatment in patients with huge unresectable HCC. Since 2000 to 2005, patients with huge (size >8cm) unresectable HCC were enrolled. Fifty-eight patients received HAIC and 44 patients received symptomatic treatment. In the HAIC group, each patient received 2.4+1.4 (range: 1–6) courses of HAIC. Baseline characteristics and survival were compared between the HAIC and symptomatic treatment groups. The HAIC group and the symptomatic treatment group were similar in baseline characteristics and tumor stages. The overall survival rates at one and two years were 29% and 14% in the HAIC group and 7% and 5% in the symptomatic treatment group, respectively. The patients in the HAIC group had significantly better overall survival than the symptomatic treatment group (P<0.001). Multivariate analysis revealed that HAIC was the significant factor associated with the overall survival (relative risk: 0.321, 95% confidence interval: 0.200–0.515, P<0.001). None of the patients died due to immediate complications of HAIC. HAIC is a safe procedure and provides better survival than symptomatic treatment in patients with huge unresectable HCC.
登录
查看更多内容
影响因子：
4.3
作者：
Song, Do Seon;Bae, Si Hyun;Yoon, Seung Kew
通讯作者：
Yoon, Seung Kew
影响因子：
7.6
作者：
Huang, YH;Chen, CH;Wu, JC
通讯作者：
Wu, JC
影响因子：
2.5
作者：
FURUTA, T;SONODA, T;SUGIMACHI, K
通讯作者：
SUGIMACHI, K
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
1.3
作者：
Liang, Huei-Lung;Huang, Jer-Shyung;Pan, Huay-Ben
通讯作者：
Pan, Huay-Ben